Oral interferon-alpha lozenges: Final Phase II data

Final data from a double-blind, Australian Phase II trial in 200 healthy volunteers showed that once-daily oral interferon-alpha lozenges for 16 weeks missed the primary endpoint of significantly reducing the incidence of influenza-like illness vs. placebo (54.5% vs. 62.6%, p=0.25). Oral interferon-alpha lozenges did significantly reduce the incidence of moderate to severe fever and head congestion vs. placebo (p<0.05). ...